dc.contributor.authors |
Yilmaz, K; Altindis, M; |
|
dc.date.accessioned |
2020-02-27T07:20:34Z |
|
dc.date.available |
2020-02-27T07:20:34Z |
|
dc.date.issued |
2017 |
|
dc.identifier.citation |
Yilmaz, K; Altindis, M; (2017). GASTROINTESTINAL MICROBIOTA AND FECAL TRANSPLANTATION. NOBEL MEDICUS, 13, 15-9 |
|
dc.identifier.issn |
1305-2381 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/65508 |
|
dc.identifier.uri |
https://doi.org/000404653300002 |
|
dc.description.abstract |
Differences in intestinal microbiota composition are detected in many cases like diabetes, allergy, autism, obesity, gastric cancer, hypertension and autoimmune diseases. Thus, regulation of healthy intestinal microbiota is a current treatment alternative in disease control. In immediate future, microbiota will frequently be used as a marker in diagnosis or as an approved treatment method by Food and Drug Administration (FDA). In this review formation and development of intestinal microbiota, its relationship with pathogenesis of diseases and current situation of fecal transplantation will be discussed. |
|
dc.language |
Turkish |
|
dc.publisher |
NOBEL ILAC |
|
dc.subject |
General & Internal Medicine |
|
dc.title |
GASTROINTESTINAL MICROBIOTA AND FECAL TRANSPLANTATION |
|
dc.type |
Article |
|
dc.identifier.volume |
13 |
|
dc.identifier.startpage |
9 |
|
dc.identifier.endpage |
15 |
|
dc.contributor.department |
Sakarya Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri Bölümü |
|
dc.contributor.saüauthor |
Altındiş, Mustafa |
|
dc.relation.journal |
NOBEL MEDICUS |
|
dc.identifier.wos |
WOS:000404653300002 |
|
dc.contributor.author |
Kerem Yilmaz |
|
dc.contributor.author |
Altındiş, Mustafa |
|